Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > SurModics and Brookwood License Nanotechnology Drug Delivery System

Abstract:
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Brookwood Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from PharmaSol GmbH of Berlin, Germany. Under the agreement, Brookwood has exclusive rights to all pharmaceutical applications of the technology.

SurModics and Brookwood License Nanotechnology Drug Delivery System

EDEN PRAIRIE, MN | Posted on July 14th, 2008

The PharmaSol technology can be used to formulate drugs into nanostructured lipid carriers (NLCsTM), which offer a number of advantages over other drug delivery nanotechnologies such as liposomes, emulsions and solid lipid nanoparticles. These advantages include increased drug loading, improved drug incorporation and the ability to produce suspensions of higher solids content, allowing for decreased dose size and products with longer shelf life. NLC formulations of drugs can be administered orally, as well as through intravenous or subcutaneous injection. Brookwood is currently offering this technology to potential customers, while also generating additional data to accelerate product development of the NLC drug delivery platform.

"This license further broadens the drug delivery technology offerings of SurModics and Brookwood and complements our existing portfolio," said Arthur J. Tipton, Ph.D., president of Brookwood. "Our microparticle technology has demonstrated multi-day to multi-month delivery; incorporating this NLC technology can enable shorter-duration injectable delivery, targeted delivery and high value oral applications for nearly all therapeutic areas. The license agreement with PharmaSol demonstrates our commitment to offering leading-edge proprietary technologies to our customers."

Professor R.H. Müller, Ph.D., the inventor of the technology and founder of PharmaSol, is a recognized leader in the field of lipid nanotechnology. Dr. Müller stated, "I am delighted we have executed this license agreement. Brookwood has exceptional capabilities in particle technology, including scale-up and manufacturing. With this collaboration, we can accelerate the development of NLC lipid technology and expand its use into a broad range of clinical applications including oncology, central nervous system (CNS) and cardiovascular."

"NLC technology broadens the nanotechnologies that we can offer to customers in need of drug delivery solutions," stated Thomas R. Tice, Ph.D., vice president of research of Brookwood. "Many promising drug candidates do not reach commercialization because they will not dissolve in the stomach or intestinal tract. NLCs are designed to increase solubility of poorly soluble drugs, thus improving oral bioavailability. Additionally, injectable NLC formulations can time release drugs for up to 7 days."

About Nanotechnology

Nanotechnology, sometimes referred to as the science of the extremely small, has across-the-board economic and quality-of-life implications. A nanometer is one-billionth of a meter. Human hair is approximately 80,000 nanometers wide. Nanoscale materials are currently used in electronic, cosmetic, automotive and medical products. Many more products, future technologies and manufacturing techniques involving nanoscience are being researched and developed around the world.

####

About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit www.surmodics.com. The content of SurModics’ website is not part of this release or part of any filings the company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the following: (1) realizing the full potential benefits of the company’s agreement with Merck & Co., Inc. requires the development of new products and applications of technology; (2) costs or difficulties relating to the integration of the businesses of Brookwood Pharmaceuticals and BioFX Laboratories with SurModics’ business may be greater than expected and may adversely affect the company’s results of operations and financial condition; (3) developments in the regulatory environment, as well as market and economic conditions, and our reliance on third parties, may adversely affect our business operations and profitability, and the company’s ability to achieve our fiscal 2008 corporate goals and to realize the potential of our pipeline; and (4) other factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

For more information, please click here

Contacts:
SurModics, Inc.
Phil Ankeny, Senior VP and Chief Financial Officer
(952) 829-2700

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Nanomedicine

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016

Announcements

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Patents/IP/Tech Transfer/Licensing

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project